Skip to main content
Clinical Trials/JPRN-UMIN000051670
JPRN-UMIN000051670
Not yet recruiting
未知

A multicenter retrospective observational study to evaluate the efficacy and safety of durvalumab following concurrent chemoradiotherapy for stage III non-small cell lung cancer harboring EGFR mutation (NEJ063 study) - NEJ063 study

Tohoku University Hospital0 sites300 target enrollmentJuly 20, 2023

Overview

Phase
未知
Intervention
Not specified
Conditions
on-small cell lung cancer
Sponsor
Tohoku University Hospital
Enrollment
300
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 20, 2023
End Date
March 31, 2026
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • (1\) Cases treated with sequential combination of chemotherapy and radiotherapy. (2\)Cases that the physician judged to be inappropriate for reasons such as inability to collect the information necessary to fill out the CRF.

Outcomes

Primary Outcomes

Not specified

Similar Trials